Hematologic- and oncologic-associated rheumatic syndromes
With the increased usage of immune checkpoint inhibition for the management of malignancies, rheumatologists and oncologists increasingly encounter patients with rheumatologic immune-related adverse events (IRAE). This lecture covers the history and development of immune checkpoint inhibitors (ICI), current uses and complications of these agents, and new checkpoint inhibitors in development. Faculty will present the perspectives of both an oncologist and rheumatologist on the challenges they have encountered when patients develop rheumatologic IRAE, while being treated with ICI--therapies that are often highly effective treatments of their malignancies. This session will review strategies for managing these adverse events in this patient population.